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The only known rBAT-associated light chain is b 0,ϩ AT. The heterodimer travels to the plasma membrane, where it mediates high-affinity transport of cystine and dibasic amino acids in a tightly coupled equimolar exchange with neutral amino acids (b 0,ϩ -like system). This activity allows accumulation of cystine and dibasic amino acids (8) . A defective b 0,ϩ -like system, localized at the apical border of proximal tubule cells, explains the cystinuria phenotype (32) . However, several lines of research questioned the role of the rBAT-b 0,ϩ AT heterodimer in vivo. First, the phenotypes of type I and non-type I cystinuria are not identical; i.e., type I cystinuria is a completely recessive disease whereas non-type I cystinuria is incompletely recessive (34) . Second, both rBAT and b 0,ϩ AT are expressed at the apical border of the proximal tubule cells, but they display opposite expression gradients rBAT expression increases from the S1 to the S3 segment, and the reverse holds for b 0,ϩ AT (7, 18, 29, 35) . Third, Ganapathy and colleagues (42, 43) found b 0,ϩ -like amino acid transport induction in cells transiently expressing both b 0,ϩ AT and 4F2hc, although other teams did not find this interaction (7, 14, 35) . Moreover, rBAT-b 0,ϩ AT heterodimers have only been reported on coexpression in cell culture lines and oocytes (Ref. 35 ; Ferná ndez E, Palacín M, and Chillarón J, unpublished observations). Thus direct in vivo evidence of this heterodimer is still lacking. Because of the above concerns, several authors have speculated that other heavy or light subunits may interact with b 0,ϩ AT or rBAT, respectively, in different segments of the proximal tubule (7, 10, 52) .
Here, we use antibodies directed against b 0,ϩ AT and rBAT to demonstrate for the first time that they indeed form a rBAT-b 0,ϩ AT heterodimer in kidney brush-border membranes. Quantification of the interaction shows that rBAT is the only b 0,ϩ AT-associated heavy subunit and suggests that there is another rBAT-associated light chain. On the basis of these results and the genetic and early physiological data from cystinuria patients, we conclude that the rBAT-b 0,ϩ AT heterodimer is responsible for most, if not all, renal cystine reabsorption.
MATERIALS AND METHODS
Antibodies and reagents. The monoclonal antibody 6-1-13 against human 4F2hc was a kind gift from Drs. Y. Ito and M. Tsurudome (Dept. of Microbiology, Mie Univ. School of Medicine, Mie-Ken, Japan). The polyclonal antibodies against mouse rBAT and human b 0,ϩ AT are described elsewhere (16, 18) . The polyclonal antibodies against human rBAT and mouse b 0,ϩ AT were produced in rabbits. The peptides used as antigens were 1-MAEDKSKRDSIEMSMKG-17 and 1-ME-ETSLRRRREDEKSTHS-18, respectively. Cysteines were introduced to facilitate keyhole limpet hemocyanin conjugation. The preimmune antisera used in the study were obtained from the same rabbits. The P4N1 polyclonal antibody against the peptide 13-PEVETSPLGDGASPGPEQVK-32 from human y ϩ LAT1 was produced at Research Genetics and used as a nonspecific control in the immunopurification experiments.
CnBr-activated Sepharose CL-4B was purchased from Amersham Pharmacia Biotech. Other general laboratory products were purchased from Sigma.
Brush-border membrane preparations. Preliminary evidence showed that rBAT and b 0,ϩ AT were unequivocally detected only after enrichment in brush-border membranes. These were prepared by the Ca 2ϩ precipitation method (25) . N-ethylmaleimide at 5 mM was present in all buffers used (except in the resuspension buffer) following Tate and colleagues (55) , to prevent artifactual reduction/shuffling of disulfides. The membranes were kept at Ϫ80°C until use.
Mouse kidney brush-border membranes were obtained from the cortex and medulla of male CD1 mice (24-26 g ). The human biopsies were obtained during nephrectomy from three human renal cell carcinoma patients. The samples were taken from tumor-free regions of the tissue. The protocol was approved by the Ethics Committee of the Fundació Puigvert.
Western blot analysis and immunoprecipitation. The protein content of the membrane preparation was measured by the method of Bradford (4) using ␥-globulin as a standard. SDS-PAGE was performed according to Laemmli (23) in the absence or presence of 100 mM dithiothreitol (DTT). Proteins were transferred to an Immobilon membrane (Millipore), which was blocked with 5% nonfat dry milk and incubated with the various antibodies. The immune complexes were detected with a horseradish peroxidase-conjugated secondary antibody (Jackson Immunochemicals) followed by enhanced chemiluminescence (Amersham Pharmacia Biotech). Measurements were performed with Phoretix software under conditions in which detection was in the linear response range.
For immunoprecipitations, 100-200 g of brush-border membranes were solubilized at 1 g/l in RIPA buffer (50 mM Tris, pH 8, 150 mM NaCl, 0.5% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS) in the presence of protease inhibitors (1 g/ml pepstatin and leupeptin, 1 U/ml aprotinin, and 1 mM phenylmethylsulfonyl fluoride). For denaturing immunoprecipitations, the membranes were boiled for 5 min in 50 mM Tris, pH 8, with 1% SDS, and 15 vol of diluting buffer (50 mM Tris, pH 8, 150 mM NaCl, 1% Triton X-100) were added. After 1 h at 4°C, both kinds of lysates were cleared by centrifugation at 10,000 g for 10 min at 4°C. The supernatants were used for the immunoprecipitation. Eight microliters of serum or 40 g of protein A-purified IgGs were used. In both cases, the antibody was coupled at 4°C to protein A-Sepharose. Solubilized membranes were then incubated with the coupled antibody (or the preimmune antisera) for 90 min at 4°C. The pellets were washed four times in RIPA (or diluting buffer) and twice in 50 mM Tris, pH 8, and then Laemmli sample buffer (either with or without 100 mM DTT) was added and the pellets were boiled to elute antigenic complexes. In some cases, the supernatants from the immunoprecipitations were subjected to a second round of immunoprecipitation performed in the same way.
Immunopurification of b 0,ϩ AT from mouse brush-border membranes. Mouse brush-border membranes (50 mg) were solubilized at 1 mg/ml in RIPA as above. The solubilized membranes were incubated overnight at 4°C with 7.5 mg of P4N1 antibody IgGs covalently coupled to Sepharose CL-4B at 5 mg/ml according to the manufacturer's instructions. The cleared material was then incubated overnight at 4°C with 7.5 mg of anti-mouse b 0,ϩ AT IgGs coupled as before. The P4N1 and the anti-b 0,ϩ AT beads were applied to columns and washed in 40 vol of RIPA buffer, 20 vol of RIPA containing 0.3 M NaCl, and 20 vol of preelution buffer (10 mM Tris, pH 8, 0.5% sodium deoxycholate, 0.1% SDS). Elution was performed at room temperature with 2 vol of 50 mM diethylamine, pH 11.5, and 0.1% sodium deoxycholate and collected in 200-l fractions. Purification was verified by Western blot analysis of 2% of each fraction with the anti-mouse b 0,ϩ AT antibody. The appropriate fractions were pooled, concentrated to 40 l using ultrafiltration with a Centricon with a 10-kDa cutoff, subjected to reducing SDS-PAGE, and silver stained (21) .
Mass spectrometry and peptide sequencing. Bands were manually excised, reduced with 10 mM DTT, alkylated with 55 mM iodoacetamide, and digested with trypsin (Promega, Madison, WI) at 37°C. The peptides were extracted with acetonitrile/trifluoroacetic acid (21, 48) , and the sample was evaporated to a volume of 20 l. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MS) was performed using a Voyager DE-PRO (Applied Biosystems, Barcelona, Spain) in the reflectron mode. Spectra were externally mass calibrated using a standard peptide mixture.
For the analysis, 0.5 l of the peptide extract and 0.5 l of matrix were loaded in the matrix-assisted laser desorption/ ionization plate.
Automated protein sequencing was performed on a Finnigan LCQ ion trap mass spectrometer (ThermoQuest, Barcelona, Spain) equipped with a homemade microspray source. For chromatography, a custom-made fused silica capillary column (Kromasil C8, 5 cm ϫ 150 m) was used (31) . Chromatographic solvents consisted of 1% acetic acid in water (solvent A) and 1% acetic acid in acetonitrile/water, 80:20 (vol/vol), (solvent B). The peptide extract was analyzed using a linear gradient from 0 to 55% of solvent B at a flow rate of 1 l/min. Tandem MS was performed using an automated data-dependent MS/MS procedure, which consisted of three scan events: a full MS scan, a high-resolution zoom scan on the most abundant ion from the full MS scan, and an MS/MS experiment on this ion (15) .
Protein Prospector v 3.4.1 software (UCSF Mass Spectrometry Facility, University of California) was used for protein identification. GenBank was used for the search.
RESULTS
The expression of rBAT and b 0,ϩ AT and their possible interaction in the kidney were analyzed by Western blotting and immunoprecipitation of human and mouse kidney brush-border membranes.
After Western blot analysis in reducing conditions, b 0,ϩ AT appeared as two main bands of 38 and 82 kDa (Fig. 1) . The highly hydrophobic character of the protein may account for its faster mobility in SDS gels (its predicted size is 53.5 kDa), as has been shown for other members of the same family (27) . The 82-kDa band is consistent with an SDS-resistant dimer. Other light subunits behave similarly (Ferná ndez E and Palacín M, unpublished observations). The relative amount of the two bands varied widely depending on the buffer used for resuspension or solubilization of the membranes before SDS-PAGE. In nonreducing conditions, b 0,ϩ AT ran as two bands of 130 and 250 kDa (Fig. 1) . Their relative amount also varied depending on the resuspension buffer or the detergents used for solubilization. Both bands were sensitive to N-glycosidase F (data not shown), suggesting that they were complexes of b 0,ϩ AT, which itself is unglycosylated, and a glycoprotein. In nonreducing conditions, rBAT was also seen as two bands of 130 and 250 kDa, which shifted to a single 96-kDa band in reducing conditions (Fig. 1) . In the absence of DTT, neither rBAT nor b 0,ϩ AT was found in monomeric form, even with high exposures. No significant differences were found between the two species tested (Fig. 1, A and B) . These results confirmed earlier data from rodents (7) and extend it to humans but did not demonstrate heterodimerization of b 0,ϩ AT and rBAT. It also has to be kept in mind that despite the fact that there are six different light subunits that heterodimerize with 4F2hc (10, 52) and at least some of them should be coexpressed in the same cell, SDS-PAGE analysis did not distinguish between different 4F2hc-light chain complexes (19, 26) . Direct coimmunoprecipitation experiments must be performed to demonstrate heterodimerization between a given pair of light and heavy subunits.
Solubilized human brush-border membranes were subjected to immunoprecipitation. Antisera against human b 0,ϩ AT, but not its preimmune antisera, immunoprecipitated b 0,ϩ AT protein ( Fig. 2A) . Under these conditions, rBAT was coprecipitated. The reverse experiment was also performed with an antibody directed against rBAT, which also coprecipitated the b 0,ϩ AT protein (Fig. 2B) . Immunoprecipitation under denaturing conditions gave the same results (not shown), indicating that the interaction was of a covalent nature. This demonstrated that rBAT and b 0,ϩ AT form a heterodimer in vivo. We attempted to quantify the rBATb 0,ϩ AT heterodimer: two consecutive rounds of immunoprecipitation with the antibody against rBAT depleted the protein from the membranes. Under these AT in the reducing condition, where 10% gels were used. B: procedure identical to that in A, except that brush-border membranes were from mouse and antibodies were specific for mouse proteins.
conditions, no more than 5% of b 0,ϩ AT remained in the supernatant (Fig. 2B) . Although the antibody against b 0,ϩ AT also fully depleted the protein from the membranes, the amount of coprecipitated rBAT widely varied among the three different kidney biopsies used (from 30% to Ͼ80% of the rBAT present in the membranes). Certainly, interpretation of these data is hampered by the heterogeneity of the biopsies. Nevertheless, the results suggest that most of the b 0,ϩ AT protein was associated with rBAT, whereas a significant fraction of rBAT may not heterodimerize with b 0,ϩ AT. 4F2hc protein is localized to the basolateral membrane of tubule cells in the kidney (41, 44) . Ganapathy and co-workers (42, 43) reported a functional association of transiently expressed b 0,ϩ AT and 4F2hc, although this result awaits confirmation (7, 14, 35) . Our brush-border preparations contained 4F2hc, most likely from basolateral membranes, because it was not enriched compared with a preparation of total membranes. Under the conditions in our study, we were unable to coprecipitate any 4F2hc with either b 0,ϩ AT or rBAT (Fig. 2) .
Because the human kidney samples were not homogeneous, we performed similar experiments with solubilized mouse brush-border membranes (Fig. 3) . It is in this model, and in rats, that the opposite expression gradients of rBAT and b 0,ϩ AT are well documented (7, 18, 35) . In humans (29) , the data for b 0,ϩ AT agree with the rodent model, whereas no information is available on rBAT. As with human membranes, we obtained similar results when the solubilization of mouse membranes was done in denaturing conditions. Antisera against mouse b 0,ϩ AT, but not its preimmune antisera, immunoprecipitated all the protein, as shown by two consecutive immunoprecipitations and analysis of the supernatant (Fig. 3A) . About 70-80% of the total rBAT present in different brush-border preparations was not coprecipitated (Fig. 3A) . This was not due to rBAT dissociation from the heterodimer in the solubilization conditions used (which are not expected to reduce disulfides), because the rBAT protein in the supernatant ran, in nonreducing SDS-PAGE, with an identical size to solubilized b 0,ϩ AT and rBAT before the immunoprecipitation (Fig. 3B) . Therefore, a significant amount of rBAT (ϳ75%) may heterodimerize with a light chain other than b 0,ϩ AT. On the basis of the localization data (7, 8, 18, 35) , we conclude that the putative rBAT-X heterodimer (see Fig. 5 and DISCUSSION) may be expressed in the S3 segment.
Because the antisera did not precipitate mouse rBAT, we were unable to measure the amount of b 0,ϩ AT that formed a heterodimer with rBAT. We thus affinity purified b 0,ϩ AT with the antisera against the mouse protein in sufficient amounts to analyze copurified proteins by MS and peptide sequencing. The purification was done essentially by scaling up the immunoprecipitation procedure, under conditions in which . As a control, proteins were also precipitated with the corresponding preimmune antisera (pre). One-third of the immunoprecipitates were loaded for SDS-PAGE under reducing conditions, and the presence of rBAT, b 0,ϩ AT, and 4F2hc was assessed by Western blot analysis. In the latter case, one-sixth of the supernatant (SN) is also shown. B: 2 consecutive immunoprecipitations (P1 and P2) with specific antibodies against human rBAT were performed. As a control, the proteins were also precipitated with the corresponding preimmune antisera (pre). One-third of the precipitates and one-sixth of the supernatants were loaded for SDS-PAGE under reducing conditions, and the presence of rBAT, b 0,ϩ AT and 4F2hc was assessed by Western blot analysis as above. All gels contained 7.5% acrylamide, except for b 0,ϩ AT Western blotting, for which 10% acrylamide gels were used. Arrows denote specific bands. mouse b 0,ϩ AT was fully depleted from the sample. The brush-border preparation was the same as that used in the experiment shown in Fig. 3 . The eluted proteins were subjected to preparative SDS-PAGE and silver stained (Fig. 4A ). Only two specifically purified bands appeared in the silver-stained gel (Fig. 4A, arrows) . No other protein copurified with b 0,ϩ AT under these stringent conditions (see MATERIALS AND METHODS). The bottom band corresponded to the immunopurified b 0,ϩ AT. The top band, with a size consistent with rBAT, was analyzed by MS and peptide sequencing. Forty-one tryptic peptides were found that completely matched the mouse rBAT sequence (Fig. 4B) . The peptides covered 38% of the sequence and were distributed all along the protein sequence. No other protein peptide was found. Therefore, b 0,ϩ AT heterodimerizes in the kidney only with rBAT.
DISCUSSION
The main purpose of this study was to solve the expression paradox of rBAT and b 0,ϩ AT in the kidney, which arose in immunolocalization and in situ hybridization experiments (7, 18, 29, 35, 42) . The expression of rBAT decreases from the S3 to the S1 segment of the proximal tubule, whereas b 0,ϩ AT expression increases. Moreover, both proteins colocalize only in a few tubule sections (7, 35, 42) . The rBAT-b 0,ϩ AT heterodimer had just been shown after overexpression in cell lines and in oocytes (14, 35) , but not in the kidney.
Our results indicate that rBAT and b 0,ϩ AT are expressed solely as heterodimers in brush-border membranes (where they are localized). Coprecipitation experiments showed that the rBAT-b 0,ϩ AT heterodimer is present in human and mouse brush-border membranes. Most of the human b 0,ϩ AT was associated with rBAT. Finally, the immunopurification of mouse b 0,ϩ AT and MS of copurified proteins directly showed that it heterodimerizes exclusively with rBAT. In contrast, rBAT may have another light subunit partner. The hypothesis that a different heavy subunit formed a heterodimer with b 0,ϩ AT in S1 and S2, proposed by several authors including ourselves (7, 10, 52), is ruled out. Moreover, we were unable to coprecipitate any 4F2hc protein from the brush-border membranes (where it was still present) with either rBAT or b 0,ϩ AT, as might be expected given the basolateral localization of 4F2hc in the kidney (41, 44) . This argues strongly against any physiological significance for the functional interaction of 4F2hc and b 0,ϩ AT in heterologous cell systems (42, 43) , which may be interpreted as the result of the overexpression of both proteins. In any case, our data do not exclude the presence of additional heavy subunit homologs that could bind other light subunits, as neither the mouse nor the human genome is complete (20) . In this sense, Kanai and colleagues (6) reported the cloning of a new light subunit, not expressed in the proximal tubule, which seemed to need a partner other than 4F2hc or rBAT.
Implications for cystine transport and the cystinuria phenotype. Earlier studies in brush-border membrane vesicles and isolated tubule fragments established that the apical transport of cystine in the mammalian kidney is mediated by two systems: one with a low K m for cystine shared with dibasic amino acids and Na ϩ independent and the other with a high K m unshared with dibasic amino acids and with a degree of Na ϩ dependence (reviewed in Ref. 49 ). After functional characterization of rBAT (2, 46, 56) , the demonstration that it is the type I cystinuria gene (5, 40) , and its main localization to the S3 segment of the proximal tubule (18) (where the low-K m system had been functionally localized) (46) , it appeared that rBAT, together with an unidentified light subunit, constituted this low-K m system (1, 13) [note that the S3 expression of rBAT did not fit with cystine reabsorption (see below)]. Although b 0,ϩ AT was later shown to be the non-type I cystinuria gene (14) , and it induced the low-K m system on coexpression with rBAT in cell lines and oocytes (7, 14, 35) , the low expression overlap with rBAT obscured the role of each protein in cystine transport in vivo. Our results are consistent with the translation of rBAT and b 0,ϩ AT expression along the proximal tubule into the expression gradients of two different rBAT heterodimers: rBAT-b 0,ϩ AT and rBAT-X (where X is most likely another light subunit) (Fig. 5) . The rBAT-b 0,ϩ AT heterodimer is expressed in decreasing amounts from the S1 to the S3 segment, like b 0,ϩ AT itself. Because Ͼ90% of cystine reabsorption occurs in early parts of the proximal tubule (49, 53) , the rBAT-b 0,ϩ AT heterodimer is the main apical cystine reabsorption system in the kidney. This conclusion is also consistent with the finding that cystinuria patients have clearance ratios of cystine/inulin (or creatinine) of ϳ1 or even slightly higher, and they reabsorb very little cystine (only occasionally Ͼ25%) (11, 17) .
The identity of the low-affinity cystine transporter is unknown. Similarly, the functional localization of the low-and high-affinity systems in studies with tubule fragments remains to be explained. There are two ways to reconcile our biochemical data with those studies First, there is a K m modulator of rBAT-b 0,ϩ AT, expressed mainly in S3 or S1, that can either increase or decrease affinity, respectively (see also Ref. 35) . This type of modulator protein has been described recently for the glutamate transporter excitatory amino acid carrier 1 (24) . However, in the case of rBAT-b 0,ϩ AT, the effector protein should also modify the interaction with Na ϩ and dibasic amino acids, which seems unlikely. Second, an Na ϩ -dependent transport system not interacting with dibasic amino acids has a lower affinity and higher capacity for cystine than rBAT-b 0,ϩ AT and is expressed mostly in S1-S2 segments. The X AG -glutamate transport system from rat alveolar type II cells carries cystine with these kinetic properties, although its molecular identity is unknown (22) . In vivo, lowaffinity cystine transport by this system would be neg- high-molecular-weight band in A was processed for mass spectrometry and peptide sequencing. The amino acid sequence of mouse rBAT is presented, with the sequenced tryptic peptides underlined and printed in bold. Of the sequence, 38% or 261 amino acids were sequenced. All of them matched the mouse rBAT sequence (accession no. AAH13441).
ligible, as expected from cystine reabsorption data in cystinuria (see above), because of the inability of cystine to compete with the other substrates of this transporter. Therefore, cystine transport would be detected only under conditions in which those other substrates were not present, as in brush-border membrane vesicle and proximal tubule fragment experiments (3, 46, 47, 53) . It would be interesting to reproduce those experiments under conditions in which amino acid concentrations in both the lumen and the peritubular solutions are closer to the physiological conditions. The X protein from the putative rBAT-X heterodimer is most likely a member of the light subunit family because it has the same electrophoretic mobility as b 0,ϩ AT (Fig. 1, ϪDTT) . From the known light subunits, only b 0,ϩ AT and asc-2 are, like rBAT, localized to the apical membrane. The subunit asc-2 is not expressed in the proximal tubule, precluding its association with rBAT (6) . The other light subunits are either localized to the basolateral membrane or not expressed in epithelial cells, and some of them have been experimentally shown not to interact with rBAT (10, 36, 51) . Therefore, we believe that the X protein is an as yet unidentified light subunit. The rBAT-X heterodimer is most likely expressed in increasing amounts from S1 to the S3 segment, as rBAT itself (see Fig. 5 ). Whether it also participates in cystine reabsorption remains to be seen. We suggest that it does not for three reasons: 1) the expression gradient of rBAT-X is not consistent with the bulk of the reabsorption process taking place at the S1 segment; 2) if rBAT-X transported cystine, non-type I homozygous cystinuria patients (with no defect in rBAT-X) would excrete less and reabsorb significantly more cystine than type I patients (with defective rBAT-X due to rBAT mutations), which is not the case (11, 16, 17, 34) ; and 3) mutations in the coding region of rBAT and b 0,ϩ AT explain ϳ80% of the reported cases, leaving only a very small gap for another cystinuria gene (16, 33) . However, we cannot rule out the possibility that rBAT-X has a minor role in cystine reabsorption. If rBAT-X does not transport cystine, hyperexcretion of the rBAT-X substrate or a metabolite would be expected in the urine of type I patients. This may not lead to any further clinical phenotype and may have been overlooked. Thus the transport specificity of rBAT-X awaits the identification of the light subunit and coexpression with rBAT.
The exclusive association of b 0,ϩ AT with rBAT limits the molecular explanations for the incomplete recessiveness of non-type I cystinuria. rBAT mutations may have milder effects than b 0,ϩ AT mutations. Most, if not all, rBAT mutants studied so far are trafficking mutants that may retain partial activity (9, 28) , whereas b 0,ϩ AT mutants are believed to have a more severe effect on transport. Alternatively, mutant b 0,ϩ AT may have a dominant negative effect on wild-type b 0,ϩ AT. It is difficult to understand why rBAT mutants would not have such a dominant effect, although several models can be envisaged. Further research on the structurefunction and cell biology interactions of rBAT with b 0,ϩ AT is needed. These studies are presently under way. Finally, more detailed studies on cystine transport and reabsorption in the kidney await the availability of mouse knockout models of type I and nontype I cystinuria. 0,ϩ AT heterodimers: implications for cystine transport and reabsorption in the kidney. A, top: scheme of a mammalian proximal tubule. The proximal convoluted tubule (pct), starting from the glomerulus (g), encompasses segments S1 and S2, and the proximal straight tubule (pst) is equivalent to segment S3. In general, Ͼ90% of amino acid reabsorption takes place in the proximal convoluted tubule, which applies also for cystine (49, 53) . Bottom: evidence from immunofluorescence studies and in situ hybridization revealed opposite expression gradients for b 0,ϩ AT and rBAT (7, 18, 29, 35) AT heterodimer accounts for 20%, and the rBAT-X heterodimer for 80%, of the total rBAT. Whether the minimum rBAT expression point is still higher than the highest b 0,ϩ AT expression point is not known. When cystine reabsorption data in normal probands and in cystinuria patients are taken into account (see DISCUSSION) , it becomes evident that the correlation of rBAT-b 0,ϩ AT heterodimer expression with cystine transport and reabsorption is most likely a direct link. ?, Unknown identity of X.
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